Sign In
Buy PHGE
$0.184
-0.0046 (-2.44%)
At Close: Jul 31, 2026
BiomX Inc. Announces 1-for-19 Reverse Stock Split
04:31pm, Friday, 14'th Nov 2025
NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targe
BiomX Inc. (PHGE) Q3 2025 Earnings Call Transcript
10:31am, Wednesday, 12'th Nov 2025
BiomX Inc. ( PHGE ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Marina Wolfson - CFO & Secretary Jonathan Solomon - CEO & Director Conference Call Participants Joseph Pant
BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates
07:30am, Wednesday, 12'th Nov 2025
Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success
BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
08:30am, Friday, 17'th Oct 2025
BiomX believes that it has fully addressed the FDA's queries related to the third-party nebulizer used to deliver BX004, which are narrow in scope; an additional FDA request for limited technical clar
BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis
08:19am, Tuesday, 19'th Aug 2025
U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns were raised in the clinical hold notificatio
BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript
11:48am, Wednesday, 13'th Aug 2025
BiomX Inc. (NYSE:PHGE ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Jonathan Eitan Solomon - CEO & Director Marina Wolfson - CFO & Secretary Conference Call Partic
BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates
06:30am, Wednesday, 13'th Aug 2025
Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
08:30am, Wednesday, 06'th Aug 2025
NESS ZIONA, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapi
First patient dosing in Company's Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections in Cystic Fibrosis patients; topline result
Premier research journal article provides validation for BiomX's phage therapy platform, showcasing first-in-human Phase 1b/2a trial results for antibiotic-resistant P. aeruginosa infections New, upda
BiomX : Introduction
10:02am, Monday, 09'th Jun 2025
Clinical Stage Programs Addressing Urgent Need for Overcoming Antibiotic Resistance Corporate Presentation June 2025 aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); NYS
BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
10:02am, Monday, 19'th May 2025
Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) Presentation to Focus on Positive Topline Results from Phas
BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript
04:57pm, Thursday, 15'th May 2025
BiomX Inc. (NYSE:PHGE ) Q1 2025 Earnings Conference Call May 15, 2025 2:00 PM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Joe Pantginis - H.C. Wain
BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
06:30am, Thursday, 15'th May 2025
In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO)
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
07:00am, Thursday, 08'th May 2025
NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapie
